These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 8428414)

  • 1. The role of percutaneous nephrostomy in malignant urinary tract obstruction.
    Watkinson AF; A'Hern RP; Jones A; King DM; Moskovic EC
    Clin Radiol; 1993 Jan; 47(1):32-5. PubMed ID: 8428414
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of percutaneous nephrostomy in malignant ureteric obstruction.
    Wilson JR; Urwin GH; Stower MJ
    Ann R Coll Surg Engl; 2005 Jan; 87(1):21-4. PubMed ID: 15720902
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Percutaneous nephrostomy in the management of malignant ureteral obstruction secondary to bladder cancer.
    Ekici S; Sahin A; Ozen H
    J Endourol; 2001 Oct; 15(8):827-9. PubMed ID: 11724123
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Percutaneous nephrostomy for ureteric obstruction due to advanced pelvic malignancy: have we got the balance right?
    Misra S; Coker C; Richenberg J
    Int Urol Nephrol; 2013 Jun; 45(3):627-32. PubMed ID: 23666587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Survival and quality of life after percutaneous nephrostomy for malignant ureteric obstruction in patients with terminal cervical cancer.
    Emmert C; Rassler J; Köhler U
    Arch Gynecol Obstet; 1997; 259(3):147-51. PubMed ID: 9187468
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Percutaneous nephrostomy in obstructing pelvic malignancy does not facilitate further oncological treatment.
    Folkard SS; Banerjee S; Menzies-Wilson R; Reason J; Psallidas E; Clissold E; Al-Mushatat A; Chaudhri S; Green JSA
    Int Urol Nephrol; 2020 Sep; 52(9):1625-1628. PubMed ID: 32319003
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maintaining quality of life after palliative diversion for malignant ureteral obstruction.
    Markowitz DM; Wong KT; Laffey KJ; Bixon R; Nagler HM; Martin EC
    Urol Radiol; 1989; 11(3):129-32. PubMed ID: 2480679
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Urinary tract obstruction and nephrostomy drainage in pelvic malignant disease.
    Lau MW; Temperley DE; Mehta S; Johnson RJ; Barnard RJ; Clarke NW
    Br J Urol; 1995 Nov; 76(5):565-9. PubMed ID: 8535673
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of percutaneous nephrostomy in malignant ureteric obstruction.
    Chapman ME; Reid JH
    Br J Radiol; 1991 Apr; 64(760):318-20. PubMed ID: 2025771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Role of percutaneous nephrostomy (PCN) in malignant ureteral obstruction.
    Jalbani MH; Deenari RA; Dholia KR; Oad AK; Arbani IA
    J Pak Med Assoc; 2010 Apr; 60(4):280-3. PubMed ID: 20419970
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic model for predicting survival after palliative urinary diversion for ureteral obstruction: analysis of 140 cases.
    Ishioka J; Kageyama Y; Inoue M; Higashi Y; Kihara K
    J Urol; 2008 Aug; 180(2):618-21; discussion 621. PubMed ID: 18554655
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Percutaneous nephrostomy for bilateral ureteric obstruction in carcinoma of the cervix. A case report.
    de Franca Martins A; Graubard Z; Ballot DE
    S Afr Med J; 1987 May; 71(10):661-2. PubMed ID: 3576393
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Percutaneous nephrostomy in gynecologic oncology patients.
    Soper JT; Blaszczyk TM; Oke E; Clarke-Pearson D; Creasman WT
    Am J Obstet Gynecol; 1988 May; 158(5):1126-31. PubMed ID: 2453117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical Factors Associated With a Short Survival Time After Percutaneous Nephrostomy for Ureteric Obstruction in Cancer Patients: An Updated Model.
    Alawneh A; Tuqan W; Innabi A; Al-Nimer Y; Azzouqah O; Rimawi D; Taqash A; Elkhatib M; Klepstad P
    J Pain Symptom Manage; 2016 Feb; 51(2):255-61. PubMed ID: 26497918
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Percutaneous nephrostomy at the Second Kaunas Clinical Hospital].
    Matjosaitis A; Rinkūnas G; Bosas P
    Medicina (Kaunas); 2002; 38 Suppl 1():76-8. PubMed ID: 12556641
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Percutaneous nephrostomy: its value in obstructive uropathy complicating carcinoma of cervix uterus.
    Chan S; Robinson AC; Johnson RJ
    Clin Oncol (R Coll Radiol); 1990 May; 2(3):156-8. PubMed ID: 2261404
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors Affecting Survival Outcome After Percutaneous Nephrostomy as Palliative Urinary Diversion in Obstructive Uropathy due to Advance Cervical Cancer Patients.
    Noegroho BS; Kurniawan AP; Wijayanti Z; Mustafa A
    Asian Pac J Cancer Prev; 2021 Apr; 22(4):1211-1216. PubMed ID: 33906314
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Palliative Subcutaneous Tunneled Nephrostomy Tube (PSTN): a simple and effective technique for management of malignant extrinsic ureteral obstruction.
    Bell DG; Fischer MA
    Can J Urol; 2002 Feb; 9(1):1470-4. PubMed ID: 11886602
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Endoluminal therapy for bilateral malignant ureteric obstruction].
    Liu YD; Yuan J; Huang ST; Luo JT; Zeng GH; Xun L
    Zhonghua Zhong Liu Za Zhi; 2007 Sep; 29(9):717-9. PubMed ID: 18246808
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of ureteral obstruction in primary cervical cancer.
    Lee SK; Jones HW
    Int J Gynaecol Obstet; 1994 Jan; 44(1):59-65. PubMed ID: 7907060
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.